C-Reactive Protein Testing Market Report 2026

C-Reactive Protein Testing Market Overview

• C-Reactive Protein Testing market size has reached to $3.52 billion in 2025 • Expected to grow to $4.48 billion in 2030 at a compound annual growth rate (CAGR) of 4.9% • Growth Driver: Cardiovascular Disease Epidemic And The Vital Role Of C-Reactive Protein Testing In Market Growth • Market Trend: Adoption of High Sensitivity CRP Testing for Early Cardiovascular Risk Assessment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under C-Reactive Protein Testing Market?

C-reactive protein testing measures the level of c-reactive protein (CRP) in the blood. CRP is a liver-produced protein released into the bloodstream due to inflammation. When the body is wounded or infected, inflammation is the body's way of protecting the tissues. CRP testing is generally used to diagnose inflammation caused due to an infection. The main types of assays in c-reactive protein testing market are enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA) and immunoturbidimetric assays. The enzyme-linked immunosorbent assay (ELISA) is used to measure CRP (c-reactive protein). C-reactive protein (CRP) ELISA test offers quantitative measurement of human c-reactive protein in serum to help in the follow-up of rheumatic fever, inflammatory processes, and others. Elisa is a biological assay that measures antibodies, antigens, proteins, and glycoproteins. The c-reactive protein testing is mainly used in clinics, hospitals and diagnostic laboratories for diseases such as diabetes, rheumatoid arthritis, cardiovascular disease, inflammatory bowel disease, cancer and others.

What Is The C-Reactive Protein Testing Market Growth Forecast?

The c-reactive protein testing market size is expected to see steady growth in the next few years. It will grow to $4.48 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing demand for point-of-care inflammatory testing, rising integration of automated diagnostics platforms, expansion of preventive healthcare screening, growing adoption of high-throughput laboratory systems, increasing focus on personalized medicine diagnostics. Major trends in the forecast period include increasing adoption of high-sensitivity crp assays, rising use of automated immunoassay systems, growing demand for rapid inflammation diagnostics, expansion of crp testing in cardiovascular risk assessment, enhanced focus on laboratory workflow automation.

What Is The Driver Of The C-Reactive Protein Testing Market?

The increase in cases of cardiovascular diseases (CVD) is expected to propel the growth of the c-reactive protein testing market going forward. Cardiovascular diseases refer to heart conditions such as diseased vessels, structural problems, and blood clots. The exact cause of CVD is uncertain, but numerous factors can increase the risk of developing it. One such factor is the behavioral risk caused by unbalanced eating, lack of physical activity, smoking, and alcohol use, which results in an accumulation of fatty deposits inside the arteries (atherosclerosis), resulting in an increased risk of blood clots. These behavioral risks result in elevated blood pressure, glucose, blood lipids, weight gain, and obesity. The increasing cases of cardiovascular diseases invite the need for c-reactive protein testing to diagnose or predict the chance of having cardiovascular problems at least as well as cholesterol levels. For instance, in October 2024, according to the Centers for Disease Control, a US-based government agency, in 2023, approximately 919,032 people died from cardiovascular disease, accounting for 1 in every 3 deaths. Therefore, the increase in cases of cardiovascular diseases (CVD) is driving the C-reactive protein testing industry.

Key Players In The Global C-Reactive Protein Testing Market

Major companies operating in the c-reactive protein testing market are Thermo Fisher Scientific Inc., F Hoffmann-La Roche AG, Danaher Corporation, Quest Diagnostics Incorporated, Siemens AG, Abbott Laboratories, Aidian Oy, Boditech Med Inc., Horiba Ltd., Laboratory Corporation, Merck KGAA, Randox Laboratories Limited, Getein Biotech Inc., Bio-Rad Laboratories Inc., DiaSorin S.p.A., Eurofins Scientific SE, Inova Diagnostics Inc., Luminex Corporation, Sekisui Diagnostics LLC, Sysmex Corporation, Tosoh Corporation, Trinity Biotech Plc, WerfenLife Group LLC, ZEUS Scientific Inc., BioMérieux SA, Biomerica Inc., Gold Standard Diagnostics Corp., Immunodiagnostic Systems Holdings PLC, Nova Biomedical Corporation

Global C-Reactive Protein Testing Market Trends and Insights

Major companies are operating in the C-reactive protein testing market, focusing on developing technological advancements such as high-sensitivity automated immunoassays for more accurate, rapid, and low-level CRP detection to support early cardiovascular risk stratification and real-time inflammation monitoring. A high-sensitivity automated immunoassay uses refined immunoturbidimetric or nephelometric techniques to detect very low CRP levels far below standard CRP assays enabling early intervention and improved prognostic evaluation. For instance, in January 2024, Siemens Healthineers, a Germany-based in vitro diagnostics company, introduced the Atellica CH High Sensitivity C-Reactive Protein 2 (hCRP2) assay for its Atellica CH Analyzer. The product comprises two ready-to-use reagent packs: one containing a phosphate buffer with surfactant, and the other containing monoclonal anti-CRP antibodies bound to polystyrene particles. When CRP in a patient sample causes aggregation of these particles, light scattering is measured, with the intensity proportional to CRP concentration. The system achieves very low-level CRP detection for cardiovascular risk stratification, is compatible with serum or plasma samples, and delivers rapid quantitative results for timely clinical decision-making.

What Are Latest Mergers And Acquisitions In The C-Reactive Protein Testing Market?

In July 2024, Roche, a Switzerland-based diagnostics company, acquired LumiraDx’s point-of-care platform for an undisclosed amount. Through this acquisition, Roche aims to strengthen its CRP testing capabilities by integrating LumiraDx’s rapid, quantitative CRP assay into its diagnostics portfolio and expanding access to point-of-care immunoassays. LumiraDx is a UK-based company that provides a multi-assay point-of-care platform, including a microfluidic immunoassay for quantitative C-reactive protein testing.

What Defines the C-Reactive Protein Testing Market?

The c-reactive protein testing market includes revenues earned by entities by devices and reagents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the C-Reactive Protein Testing Market Report 2026?

The c-reactive protein testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the c-reactive protein testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.